It’s been a year of surprises for our Vasculitis Recognizing Excellence in Diagnosis (V-RED) award program. We have two winners who tied for first place, two winners who received honorable mentions, and this is the first year we’ve had a winner from Germany and Saskatoon, Canada. This is the 10th…...
Amgen Successfully Completes Acquisition of ChemoCentryx
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat…...
